NMTC
NeuroOne Medical Technologies Corporation
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
2.31
▲ 0.16 (7.43%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.36
Prev close
2.15
Day high
2.15
Day low
2.01
Volume
34.97K
Market cap
$18.48M
P/E (TTM)
—
52W range
1.42 – 6.96
Day trading desk
Gap from prior close
+9.77%
Prior close 2.15
VWAP
2.07
+11.74% from price
Relative volume
0.66×
Normal
Session range
17.41%
2.01 – 2.36
Position in range
86%
Near session high
ATR (14D)
0.24
10.47% of price
Prior day high
2.31
PDH
Prior day low
2.15
PDL
Bid / ask spread
—
Quote not published
Session volume
33.52K
Avg 50.58K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+4.64%
+6.0%
1M
+9.73%
+6.0%
3M
-47.95%
-51.0%
6M
-50.25%
-61.3%
YTD
-55.36%
-67.7%
1Y
-54.95%
-74.9%
3Y
-66.50%
-140.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NMTC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+2.99M
Net buying
Buy transactions
48
3.54M shares
Sell transactions
15
550.39K shares
Net transactions
+63
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
2.30M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | CHRISTIANSON MARK Officer |
SELL | 10.00K | $31.77K | Direct |
| Apr 2, 26 | MATHIESEN JEFFREY S Director |
— | 41.93K | — | Direct |
| Apr 2, 26 | BUCKMAN PAUL R Director |
— | 41.93K | — | Direct |
| Apr 2, 26 | ANDRLE EDWARD Director |
— | 41.93K | — | Direct |
| Apr 2, 26 | MILLS JASON RICHARD Director |
— | 41.93K | — | Direct |
| Mar 30, 26 | CHRISTIANSON MARK Officer |
SELL | 15.36K | $11.37K | Direct |
| Mar 13, 26 | CHRISTIANSON MARK Officer and Director |
SELL | 917 | $734 | Direct |
| Mar 11, 26 | CHRISTIANSON MARK Officer |
SELL | 13.72K | $10.98K | Direct |
| Feb 27, 26 | WAMBEKE DAVID J Officer |
BUY | 1.00M | $670.40K | Direct |
| Dec 18, 25 | MILLS JASON RICHARD Director |
— | 7.76K | — | Direct |
| Sep 5, 25 | CHRISTIANSON MARK Officer |
SELL | 30.00K | $22.20K | Direct |
| Jun 4, 25 | CHRISTIANSON MARK Officer |
SELL | 10.00K | $5.80K | Direct |
| May 22, 25 | CHRISTIANSON MARK Officer |
SELL | 8.98K | $5.60K | Direct |
| May 20, 25 | CHRISTIANSON MARK Officer |
SELL | 11.02K | $7.31K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDRLE EDWARD |
Director | 133.93K | Stock Award(Grant) |
BUCKMAN PAUL R |
Director | 178.73K | Stock Award(Grant) |
CHRISTIANSON MARK |
Officer | 20.69K | Sale |
MATHIESEN JEFFREY S |
Director | 156.34K | Stock Award(Grant) |
MCCLURG RONALD W. |
Chief Financial Officer | 444.12K | Purchase |
MILLS JASON RICHARD |
Director | 49.69K | Stock Award(Grant) |
ROSA DAVID A |
Chief Executive Officer | 1.16M | Purchase |
WAMBEKE DAVID J |
Officer | 1.00M | Purchase |
Fundamentals
Market cap$18.48M
Enterprise value$16.61M
Revenue (TTM)$12.47M
Gross profit$2.87M
EBITDA$-7.66M
Net income$-7.45M
EPS (TTM)$-0.97
Free cash flow$-4.57M
Total cash$2.05M
Total debt$175.34K
Book value / share$0.43
Shares outstanding9.11M
Float6.27M
Short % of float0.46%
Dividend yield—
Beta (5Y)0.64
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.25
PEG ratio—
Price / sales—
Price / book4.69
EV / revenue1.33
EV / EBITDA-2.17
Gross margin23.00%
Operating margin-122.87%
Profit margin-59.71%
Return on equity-124.66%
Return on assets-58.07%
Debt / equity4.65
Current ratio2.84
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $9.10M | $3.45M | $1.95M | $171.17K | +163.5% |
| Operating revenue | $9.10M | $3.45M | $1.95M | $171.17K | +163.5% |
| Cost of revenue | $3.96M | $2.37M | $1.50M | $241.96K | +66.7% |
| Gross profit | $5.14M | $1.08M | $456.52K | -$70.79K | +376.2% |
| Research & development | $4.98M | $5.07M | $6.94M | $4.93M | -1.6% |
| Selling, general & admin | $7.38M | $7.90M | $6.93M | $6.98M | -6.5% |
| Total operating expense | $9.37M | $12.97M | $12.41M | $9.96M | -27.8% |
| Operating income | -$4.23M | -$11.89M | -$11.96M | -$10.03M | +64.4% |
| Net interest income | -$334.06K | -$228.99K | $0 | $0 | -45.9% |
| Pre-tax income | -$3.61M | -$12.32M | -$11.86M | -$10.00M | +70.7% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$3.61M | -$12.32M | -$11.86M | -$10.00M | +70.7% |
| Net income to common | -$3.61M | -$12.32M | -$11.86M | -$10.00M | +70.7% |
| Basic EPS | -0.54 | -2.76 | -3.90 | -3.78 | +80.4% |
| Diluted EPS | -0.54 | -2.76 | -3.90 | -3.78 | +80.4% |
| EBIT | -$3.27M | -$12.09M | -$11.86M | -$10.03M | +72.9% |
| EBITDA | -$3.01M | -$11.84M | -$11.66M | -$9.91M | +74.6% |
| Basic shares | 6.69M | 4.46M | 3.02M | 2.67M | +50.0% |
| Diluted shares | 6.69M | 4.46M | 3.02M | 2.67M | +50.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $6.57M | $1.46M | $5.32M | $8.16M | +350.0% |
| Cash & short-term investments | $6.57M | $1.46M | $5.32M | $11.14M | +350.0% |
| Accounts receivable | $1.26M | $176.64K | $0 | $33.24K | +616.1% |
| Inventory | $2.23M | $2.64M | $1.73M | $704.54K | -15.5% |
| Total current assets | $10.23M | $4.63M | $7.31M | $12.18M | +120.8% |
| Property, plant & equipment | $514.42K | $671.75K | $694.81K | $534.95K | -23.4% |
| Goodwill & intangibles | $44.95K | $67.26K | $89.58K | $111.89K | -33.2% |
| Total assets | $10.79M | $5.37M | $8.10M | $12.82M | +100.9% |
| Total current liabilities | $2.30M | $2.21M | $1.79M | $3.10M | +4.1% |
| Total debt | $266.81K | $260.16K | $184.40K | $202.90K | +2.6% |
| Total liabilities | $3.71M | $4.55M | $1.85M | $3.22M | -18.4% |
| Retained earnings | -$78.61M | -$75.00M | -$62.69M | -$50.83M | -4.8% |
| Shareholder equity | $7.07M | $822.01K | $6.25M | $9.60M | +760.4% |
| Working capital | $7.92M | $2.42M | $5.52M | $9.08M | +227.7% |
| Net tangible assets | $7.03M | $754.75K | $6.16M | $9.49M | +831.1% |
| Shares issued | 8.33M | 5.14M | 3.99M | 2.70M | +62.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$3.61M | -$12.32M | -$11.86M | -$10.00M | +70.7% |
| Depreciation & amortisation | $261.68K | $246.79K | $199.27K | $118.62K | +6.0% |
| Stock-based compensation | $1.26M | $1.34M | $1.11M | $947.21K | -5.9% |
| Change in working capital | -$429.19K | -$954.61K | -$2.43M | $1.21M | +55.0% |
| Operating cash flow | -$2.84M | -$11.01M | -$12.89M | -$7.52M | +74.2% |
| Capital expenditure | -$81.74K | -$120.20K | -$384.12K | -$275.23K | +32.0% |
| Investing cash flow | -$81.74K | -$120.20K | $2.65M | -$3.24M | +32.0% |
| Share buybacks | -$124.62K | -$81.40K | -$119.42K | $0 | -53.1% |
| Financing cash flow | $8.03M | $7.27M | $7.40M | $12.02M | +10.5% |
| Free cash flow | -$2.92M | -$11.13M | -$13.27M | -$7.79M | +73.8% |
| End cash position | $6.57M | $1.46M | $5.32M | $8.16M | +350.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.86M | $2.89M | $2.74M | $1.70M | $1.39M | — | -35.6% |
| Operating revenue | $1.86M | $2.89M | $2.74M | $1.70M | $1.39M | — | -35.6% |
| Cost of revenue | $871.79K | $1.32M | $1.21M | $781.22K | $615.49K | — | -34.2% |
| Gross profit | $990.26K | $1.57M | $1.53M | $914.84K | $771.06K | — | -36.8% |
| Research & development | $1.47M | $1.39M | $1.12M | $1.18M | $1.51M | — | +5.6% |
| Selling, general & admin | $1.92M | $1.89M | $1.78M | $1.62M | $1.94M | — | +1.8% |
| Total operating expense | $3.39M | $3.28M | $2.90M | $2.80M | $3.45M | — | +3.4% |
| Operating income | -$2.40M | -$1.71M | -$1.37M | -$1.89M | -$2.68M | — | -40.4% |
| Net interest income | $0 | $0 | $0 | -$9.32K | $0 | — | — |
| Pre-tax income | -$2.38M | -$1.44M | -$1.62M | -$1.50M | -$2.27M | — | -65.7% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$2.38M | -$1.44M | -$1.62M | -$1.50M | -$2.27M | — | -65.7% |
| Net income to common | -$2.38M | -$1.44M | -$1.62M | -$1.50M | -$2.27M | — | -65.7% |
| Basic EPS | -0.28 | -0.18 | — | -0.18 | -0.42 | 0.36 | -55.6% |
| Diluted EPS | -0.28 | -0.18 | — | -0.18 | -0.42 | 0.36 | -55.6% |
| EBIT | -$2.38M | -$1.44M | -$1.62M | -$1.49M | -$2.27M | — | -65.7% |
| EBITDA | -$2.32M | -$1.37M | -$1.55M | -$1.42M | -$2.20M | — | -69.2% |
| Basic shares | 8.48M | 8.39M | — | 8.10M | 5.19M | 5.14M | +1.1% |
| Diluted shares | 8.48M | 8.39M | — | 8.10M | 5.19M | 5.15M | +1.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.80M | $3.56M | $6.57M | $8.04M | $1.32M | -21.3% |
| Cash & short-term investments | $2.80M | $3.56M | $6.57M | $8.04M | $1.32M | -21.3% |
| Accounts receivable | $2.43M | $2.66M | $1.26M | $0 | $318.78K | -8.8% |
| Inventory | $1.87M | $1.67M | $2.23M | $1.90M | $1.83M | +12.0% |
| Total current assets | $7.40M | $8.07M | $10.23M | $10.17M | $3.75M | -8.2% |
| Property, plant & equipment | $427.37K | $471.16K | $514.42K | $598.21K | $646.50K | -9.3% |
| Goodwill & intangibles | $33.79K | $39.37K | $44.95K | $50.52K | $56.10K | -14.2% |
| Total assets | $7.86M | $8.58M | $10.79M | $10.82M | $4.46M | -8.3% |
| Total current liabilities | $1.69M | $1.26M | $2.30M | $1.43M | $1.76M | +34.2% |
| Total debt | $206.97K | $237.38K | $266.81K | $295.72K | $311.41K | -12.8% |
| Total liabilities | $2.49M | $2.18M | $3.71M | $2.64M | $3.33M | +14.5% |
| Retained earnings | -$82.13M | -$80.05M | -$78.61M | -$76.99M | -$75.49M | -2.6% |
| Shareholder equity | $5.37M | $6.40M | $7.07M | $8.18M | $1.13M | -16.1% |
| Working capital | $5.71M | $6.81M | $7.92M | $8.74M | $1.99M | -16.1% |
| Net tangible assets | $5.34M | $6.36M | $7.03M | $8.13M | $1.07M | -16.1% |
| Shares issued | 8.62M | 8.40M | 8.33M | 8.30M | 5.23M | +2.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.38M | -$1.44M | -$1.62M | -$1.50M | -$2.27M | -65.7% |
| Depreciation & amortisation | $60.03K | $65.52K | $64.32K | $66.59K | $65.63K | -8.4% |
| Stock-based compensation | $342.13K | $359.25K | $358.56K | $316.65K | $250.17K | -4.8% |
| Change in working capital | $613.40K | -$1.91M | -$675.01K | -$71.12K | $2.26M | +132.1% |
| Operating cash flow | -$1.33M | -$3.12M | -$1.53M | -$1.46M | -$56.14K | +57.4% |
| Capital expenditure | -$38.52K | -$40.75K | -$10.61K | -$43.55K | -$3.17K | +5.5% |
| Investing cash flow | -$38.52K | -$40.75K | -$10.61K | -$43.55K | -$3.17K | +5.5% |
| Share buybacks | -$60.78K | -$3.63K | -$2.77K | -$3.47K | -$107.11K | -1,573.4% |
| Financing cash flow | $609.62K | $147.82K | $66.98K | $8.23M | $245.22K | +312.4% |
| Free cash flow | -$1.37M | -$3.16M | -$1.54M | -$1.51M | -$59.31K | +56.7% |
| End cash position | $2.80M | $3.56M | $6.57M | $8.04M | $1.32M | -21.3% |
Options analytics
Put / call volume
1.00
Call-heavy session
Put / call open interest
0.21
Positioning, not flow
Max pain
2.50
+23.2% from spot
ATM implied vol
362.5%
Nearest strike to spot
Skew (10% OTM)
-232.0%
Calls bid over puts
Call volume
7
Contracts, this expiry
Put volume
7
Contracts, this expiry
Heaviest call OI
10.00
64 contracts
Heaviest put OI
7.50
13 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.22 | -0.28 | -29.2% |
| Mar 2026 | -0.23 | — | — |
| Dec 2025 | -0.24 | -0.18 | +25.0% |
| Sep 2025 | -0.24 | -0.24 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.22 | 3 | $2.81M | +2.4% |
| Next quarter | -0.17 | 3 | $3.34M | +15.6% |
| Current year | -0.74 | 3 | $9.54M | +4.8% |
| Next year | -0.63 | 3 | $13.33M | +39.8% |
Analyst targets & ownership
Mean target$7.27
High target$8.80
Low target$5.00
Implied upside214.62%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders25.23%
Held by institutions22.45%
Institutions holding28
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.86
+24.38% from price
SMA 20
1.76
+15.14% from price
SMA 50
2.41
-15.85% from price
SMA 100
3.36
-31.27% from price
SMA 200
3.95
-48.60% from price
EMA 12
1.91
+20.78% from price
EMA 26
2.01
+15.13% from price
EMA 50
2.39
-3.32% from price
RSI (14)
50.4
Neutral
MACD (12,26,9)
-0.09
Hist 0.11
ATR (14)
0.24
11.91% of price
Realised vol 30D
98.9%
Annualised
Bollinger upper
2.14
20, 2σ
Bollinger lower
1.39
20, 2σ
50 / 200 cross
Death
2.41 vs 3.95
Trend bias
Below 200
-48.60%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.78
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
98.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-76.1%
Peak to trough
Max drawdown 5Y
-95.3%
Peak to trough
ATR 14
0.24
11.91% of price
Beta (reported)
0.64
5Y monthly, from filing
Short interest
Shares short
38.70K
Prior 28.84K
Change vs prior
+34.2%
Shorts adding
% of float
0.46%
Normal
% of shares out
0.44%
Against total outstanding
Days to cover
0.8
Liquid
Float
6.27M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 26 | Maxim Group | MAINTAINED | Buy | Buy |
| May 13, 26 | Ladenburg Thalmann | MAINTAINED | Buy | Buy |
| Mar 2, 26 | Jones Trading | INITIATED | — | Buy |
| Sep 9, 25 | Maxim Group | INITIATED | — | Buy |
| May 5, 25 | Ladenburg Thalmann | INITIATED | — | Buy |
| Aug 15, 23 | Alliance Global Partners | MAINTAINED | Buy | Buy |
| Mar 28, 22 | Craig-Hallum | DOWNGRADE | Buy | Hold |
| Dec 3, 21 | Alliance Global Partners | INITIATED | — | Buy |
| Nov 15, 21 | Craig-Hallum | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:6
Split dateApr 16, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-06-12
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-05-04
Corporate Changes & Voting Matters
8-K · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-04-14
Headlines
NeuroOne (NMTC) Q3 2026 Earnings Call Transcript
Motley Fool · 3d ago
NeuroOne Medical Technologies Corp (NMTC) (Q3 2026) Earnings Call Highlights: Revenue Grows 16% ...
GuruFocus.com · 6d ago
NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary
Moby · 10d ago
NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%
NewMediaWire · 10d ago
NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification
NewMediaWire · 12d ago
NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time
NewMediaWire · 20d ago
NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED(TM) Platform
NewMediaWire · 24d ago
NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based on Reports by Physicians
NewMediaWire · 26d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.